Chemistry:Lotiglipron

From HandWiki
Short description: Chemical compound
Lotiglipron
Lotiglipron.svg
Identifiers
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC31H31ClN4O5
Molar mass575.06 g·mol−1
3D model (JSmol)

Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer.[1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.[2]

See also

References

  1. Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", US patent 10676465, issued 9 June 2020, assigned to Pfizer Inc
  2. "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns.". Time. 26 June 2023. https://time.com/6290227/pfizer-shares-drop-after-lotiglipron-pause/.